Beat the Common Cold
Researchers in Canada and China are testing a powerful immune booster that provides broad-spectrum protection against the common cold and a number of viruses including SARS, Ebola and H1N1. They’re currently running clinical trials to prove its effectiveness against coronavirus. I’m talking about quercetin – a powerful antioxidant that is already available as a supplement. Previous research shows that quercetin’s antiviral capacity works in three ways. Quercetin can: Stop the virus from infecting cells Reduce the reproduction of cells that are already infected And reduce infected cells resistance to treatment with antiviral medications Today I’ll Show You How To Use This Natural Immunity Booster To Protect Against Deadly Viral Infections Following the deadly avian flu outbreak in 2007, the U.S. Department of Defense tested quercetin to see if it could protect soldiers from contracting deadly viral infections… They gave study participants a daily dose of 1,000 mg of quercetin (along with vitamin C and niacin to boosts quercetin levels and improve bioavailability) or a placebo. They found that after five weeks, those who were given quercetin were significantly less likely to develop a viral infection after putting their bodies under considerable stress for three consecutive days. Only 5% of the treatment group got sick, compared to 45% of the placebo group.1 In a second study by the U.S. Defense Advanced Research Projects Agency (DARPA), r...
Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Cheng Han, Yinping Zhang, Marc Redmile-Gordon, Huan Deng, Zhenggui Gu, Qiguo Zhao, Fang Wang
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Peter A. Bain, Adrienne Gregg, Alok K. Pandey, Mohana Krishna Reddy Mudiam, Peta A. Neale, Anu Kumar
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Jinquan Chen, Xuan Li, Wei Jia, Shili Shen, Shengjiong Deng, Bohua Ji, Junjun Chang
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Zhongyi Zhang, Wen-Xiong Wang, Nengjian Zheng, Yansheng Cao, Hongwei Xiao, Renguo Zhu, Hui Guan, Huayun Xiao
Publication date: Available online 30 September 2020Source: Journal of Hazardous MaterialsAuthor(s): Anthony Beauvois, Delphine Vantelon, Jacques Jestin, Martine Bouhnik-Le Coz, Charlotte Catrouillet, Valérie Briois, Thomas Bizien, Mélanie Davranche
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
More News: Alzheimer's | Antidoxidants | Apples | Bird Flu | Brain | Canada Health | China Health | Clinical Trials | Common Cold | Complementary Medicine | Coronavirus | COVID-19 | Cranberry | Dengue Fever | Diabetes | Eating Disorders & Weight Management | Ebola | Elderberry | Endocrinology | Flavonoids | H1N1 | Hepatitis | Influenza | Lettuce | Men | Meningitis | Neurology | Neuroscience | Niacin | Niaspan | Nutrition | Obesity | Onions | Organic | Outbreaks | Peppers | Physiology | Pneumonia | Reproduction Medicine | SARS | Science | Sports Medicine | Study | Tomatoes | Vitamin B3 | Vitamin C | Vitamins